IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
II trial of IC41 in 50 chronic hep a ti tis C pa tients in Ger many, Po land and Ro ma nia who have not received
previous treatment.
Li cens ing: In 2007, Novartis and Intercell es tab lished a stra te gic al li ance re lat ing to the de vel op ment of
vac cines for in fec tious dis eases. The col lab o ra tion will fo cus on the de vel op ment of an ti bac te rial vac cines
de rived from Intercell’s An ti gen Iden ti fi ca tion Pro gram (AIP) and the use of Intercell’s IC31 adjuvant
tech nol ogy in se lected new vac cines. Novartis will make an upfront pay ment of Euro120 mil lion to
Intercell in op tion and li cense fees. Intercell will re ceive a Euro150 mil lion cash con tri bu tion from
Novartis, through pur chase of 4.8 mil lion Intercell shares, in creas ing Novartis’ eq uity stake in Intercell to
16.2% from the cur rent 6.1%. Novartis ac quires opt-in rights for the de vel op ment, man u fac tur ing and
com mer cial iza tion of Intercell’s non-part nered vac cine tar gets in its AIP af ter the com ple tion of phase II
tri als (or ear lier at Novartis’ elec tion). Intercell re tains the right to choose be tween co-de vel op -
ment/profit-shar ing or li cens ing with pre de fined mile stone and roy alty pay ments for AIPs that Novartis
chooses for fur ther de vel op ment. Novartis ac quires ex clu sive rights to Intercell’s IC31 adjuvant for use in
de vel op ing in flu enza vac cines. Intercell is el i gi ble for up to Euro100 mil lion in mile stones dur ing the de -
vel op ment pe riod and dou ble-digit roy al ties tied to sales per for mance. Novartis also ac quires a non-ex -
clu sive li cense to IC31 in other ar eas. Intercell will re ceive Euro30-60 mil lion dur ing the de vel op ment
pe riod in upfront pay ments and mile stones, and up to high sin gle-digit roy al ties tied to sales per for mance
for each fu ture li cense for IC31 in se lected ar eas. The agree ment also in cludes co-de vel op ment and
profit-shar ing in a collaboration to combine the hepatitis C virus (HCV) infection programs of both
companies; this includes Intercell’s IC41 vaccine.
VAC CINE, PSEU DO MO NAS AERUGINOSA: In Jan u ary 2009, Novartis re ported that it was con duct ing
phase II tri als of this vac cine in col lab o ra tion with Intercell (Austria).
Li cens ing: In 2007, Novartis and Intercell es tab lished a stra te gic al li ance re lat ing to the de vel op ment of
vac cines for in fec tious dis eases. The col lab o ra tion will fo cus on the de vel op ment of an ti bac te rial vac cines
de rived from Intercell’s An ti gen Iden ti fi ca tion Pro gram (AIP) and the use of Intercell’s IC31 adjuvant
tech nol ogy in se lected new vac cines. Novartis will make an upfront pay ment of Euro120 mil lion to
Intercell in op tion and li cense fees. Intercell will re ceive a Euro150 mil lion cash con tri bu tion from
Novartis, through pur chase of 4.8 mil lion Intercell shares, in creas ing Novartis’ eq uity stake in Intercell to
16.2% from the cur rent 6.1%. Novartis ac quires opt-in rights for the de vel op ment, man u fac tur ing and
com mer cial iza tion of Intercell’s non-part nered vac cine tar gets in its AIP af ter the com ple tion of phase II
tri als (or ear lier at Novartis’ elec tion). Intercell re tains the right to choose be tween co-de vel op -
ment/profit-shar ing or li cens ing with pre de fined mile stone and roy alty pay ments for AIPs that Novartis
chooses for fur ther de vel op ment. Novartis ac quires ex clu sive rights to Intercell’s IC31 adjuvant for use in
de vel op ing in flu enza vac cines. Intercell is el i gi ble for up to Euro100 mil lion in mile stones dur ing the de -
vel op ment pe riod and dou ble-digit roy al ties tied to sales per for mance. Novartis also ac quires a non-ex -
clu sive li cense to IC31 in other ar eas. Intercell will re ceive Euro30-60 mil lion dur ing the de vel op ment
pe riod in upfront pay ments and milestones, and up to high single-digit royalties tied to sales performance
for each future license for IC31 in selected areas.
NIM 811 is a non-immunosuppressive ciclosporin de riv a tive, in de vel op ment for the treat ment of hep a -
ti tis C vi rus in fec tion. Phase I tri als were on go ing in Eu rope in 2008.
IC31 is a syn thetic vac cine adjuvant from Intercell (Aus tria) com pris ing the antimicrobial pep tide KLK
and the immunostimulatory oligodeoxynucleotide ODN1a. The adjuvant in duces both B- and T-cell im -
mune re sponse. In July 2007, Novartis ac quired ex clu sive rights to use IC 31 to de velop in flu enza vac -
cines, as well as non-ex clu sive rights to the adjuvant in other ar eas. In June 2008, Intercell re ported the
re ceipt of a Euro2 mil lion mile stone pay ment from Novartis, trig gered by Novartis’ ini ti a tion of an
in-house clin i cal trial pro gram to dem on strate the safety and immunogenicity of a sea sonal in flu enza vac -
cine adjuvanted with Intercell’s IC 31.
© 2009 IMS Health In cor po rated or its af fil i ates Page 104